▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Mar 7, 2014 by Todd Campbell

Better Buy: Biogen Or Amgen?

Biogen (BIIB) and Amgen (AMGN) are biotech heavyweights hitting new highs. Is one a better buy than the other?

Mar 7, 2014 by Todd Campbell

The Growth Driver Johnson & Johnson Investors Need to Watch

A slate of recent wins suggest Johnson's (JNJ) pharmaceutical division remains one of the best in the business.

Mar 7, 2014 by Todd Campbell

Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2

Arrowhead is leveraging RNAi technology acquired from Roche in 2011 to develop a new therapy for hepatitis B.

Mar 5, 2014 by Todd Campbell

What You Ought To Know About Celgene's Deal-Making Magic

Celgene's investment team has made a string of savvy investments in early stage biotech companies.

Mar 5, 2014 by Todd Campbell

3 Reasons Buffett Whiz Ted Weschler Likes DaVita HealthCare Partners

Here's why Berkshire Hathaway owns shares in DaVita (DVA), a leader in dialysis and coordinated care.

Mar 5, 2014 by Todd Campbell

Has Insys Run Too Far Too Fast?

insys (INSY) Subsys, a fast selling treatment for breakthrough cancer pain, is catapulting shares to new highs, but valuation may have gotten a bit rich.

Mar 5, 2014 by Todd Campbell

AbbVie Inc. Aces Its Hep C Trial, but Is It Too Late?

AbbVie's (ABBV) phase 3 trial data is compelling; however that doesn't guarantee it will win out over competitors Gilead (GILD) and Bristol-Myers (BMY)

Mar 4, 2014 by Todd Campbell

Regeneron's Eylea: The Anatomy Of A Blockbuster Drug

Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year.

Mar 4, 2014 by Todd Campbell

Molina's Big Problem: Too Much Demand

Obamacare Medicaid membership at Molina (MOH) is pumping up costs, but profit will still climb.

Mar 3, 2014 by Todd Campbell

Was Medivation's Quarter a Disaster?

Medivation (MDVN) shares sank more than 10% on news of slowing sales growth for its prostate cancer drug Xtandi; however, an FDA decision and potential milestones may support the company into year end.

Mar 3, 2014 by Todd Campbell

Anika Therapeutics, Inc Surges On Approval, but Is It Overpriced Now?

Anika (ANIK) won FDA approval for Monovisc, but sales will have to be strong to justify its recent move higher.

Feb 28, 2014 by Todd Campbell

InterMune Stuns Markets, but Is It Overvalued?

Trial results for Intermune's Esbriet launched shares higher this month; however, the opportunity may not justify shares heading much higher from here.

Feb 28, 2014 by Todd Campbell

Better Buy: UnitedHealth Group Inc. Vs. Humana

Both United and Humana are leveraging enrollment growth for upside, but Humana may be the better buy.

Feb 27, 2014 by Todd Campbell

Eli Lilly's Dulaglutide: The Same, But Better

Lilly's (LLY) promising type 2 diabetes drug dulaglutide performed in line with Novo's top selling Victoza, opening the door for market share.

Feb 26, 2014 by Todd Campbell

Will Obamacare Derail Zimmer Holdings, Inc.?

Zimmer's hip and knee replacement products offer potential upside, offsetting fear over higher taxes.

Feb 26, 2014 by Todd Campbell

Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares

Acadia's (ACAD) promising drug for Parkison's and Alzheimer's has investors cheering

Feb 25, 2014 by Todd Campbell

Dividend Derby: Bristol-Myers Squibb Vs. AstraZeneca

Bristol-Myers and AstraZeneca offer nice dividend yields, but patent expiration may mean dividend investors are taking on risk.

Feb 25, 2014 by Todd Campbell

1 Drug Critical to Johnson & Johnson's Future Success

The recent approval of Johnson (JNJ) and Pharmacyclics (PCYC) Imbruvica for two forms of blood cancer may be just the beginning.

Feb 24, 2014 by Todd Campbell

Here's Why You Should Look Beyond NICE's Pushback on Tecfidera

The U.K.'s cost cutting agency has pushed back on Biogen's (BIIB) Tecfidera, but that shouldn't surprise you.

Feb 21, 2014 by Todd Campbell

Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle

Chelsea's Northera finally gets the nod from regulators, but whether anyone prescribes it remains to be seen.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services